mGlu2 NAM for mild neurocognitive disorders

mGlu2 NAM for the treatment of mild neurocognitive disorders (mNCD).

We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer's disease, Parkinson's disease and depressive disorders.

We are currently optimizing multiple chemical series of highly selective mGlu2 NAMs offering advanced compounds at the late stage of lead optimization.